ONCOTELIC ANNOUNCES US PATENT GRANT FOR CA4P AND OXI4503 COMBINATION WITH CHECKPOINT INHIBITORS
11. Mai 2022 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), is pleased to announce the grant of patent application no. 15/753,882...